Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
74.85
+4.13 (5.84%)
At close: Oct 8, 2025, 4:00 PM EDT
77.00
+2.15 (2.87%)
After-hours: Oct 8, 2025, 6:38 PM EDT
Palvella Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts that cover Palvella Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $66.67, which forecasts a -10.93% decrease in the stock price over the next year. The lowest target is $38 and the highest is $95.
Price Target: $66.67 (-10.93%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Palvella Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 8 | 8 | 8 |
| Buy | 1 | 1 | 1 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $56 → $80 | Strong Buy | Maintains | $56 → $80 | +6.88% | Oct 2, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $60 → $73 | Strong Buy | Maintains | $60 → $73 | -2.47% | Sep 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $75 → $95 | Strong Buy | Maintains | $75 → $95 | +26.92% | Sep 25, 2025 |
| Stifel | Stifel | Strong Buy Maintains $60 → $80 | Strong Buy | Maintains | $60 → $80 | +6.88% | Sep 24, 2025 |
| Oppenheimer | Oppenheimer | Buy Initiates $85 | Buy | Initiates | $85 | +13.56% | Sep 9, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
40.80K
EPS This Year
-3.35
from -7.83
EPS Next Year
-3.44
from -3.35
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | 420,000 | |
| Avg | n/a | 40,800 | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -3.01 | -1.88 | |
| Avg | -3.35 | -3.44 | |
| Low | -3.55 | -4.59 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.